Search

Your search keyword '"Ressico, Francesca"' showing total 13 results
Start Over Author "Ressico, Francesca"
13 results on '"Ressico, Francesca"'

2. The shocking attitude towards ECT in Italy

Author

Cattaneo, Carlo Ignazio, Ressico, Francesca, Fornaro, Michele, Fazzari, Giuseppe, Perugi, Giulio, Cattaneo, Carlo Ignazio, Ressico, Francesca, Fornaro, Michele, Fazzari, Giuseppe, and Perugi, Giulio

Published
2020

8. Suicide attempts and emergency room psychiatric consultation

Author

Zeppegno, Patrizia, primary, Gramaglia, Carla, additional, Castello, Luigi Mario, additional, Bert, Fabrizio, additional, Gualano, Maria Rosaria, additional, Ressico, Francesca, additional, Coppola, Isabella, additional, Avanzi, Gian Carlo, additional, Siliquini, Roberta, additional, and Torre, Eugenio, additional

Published
2015
Full Text
View/download PDF

10. An Observational Study of Venlafaxine and CYP2D6 in Clinical Practice

Author

Rolla, R., primary, Gramaglia, Carla, additional, Dalò, Valentina, additional, Ressico, Francesca, additional, Prosperini, Pierluigi, additional, Vidali, Matteo, additional, Meola, Silvia, additional, Pollarolo, Paola, additional, Bellomo, Giorgio, additional, Torre, Eugenio, additional, and Zeppegno, Patrizia, additional

Published
2014
Full Text
View/download PDF

13. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient

Author

Matteo Ballabio, Francesca Vittoria Ressico, Michele Fornaro, Roberta Valsesia, Carlo Ignazio Cattaneo, Pierluigi D’Innella, Cattaneo, Carlo Ignazio, Ressico, Francesca, Valsesia, Roberta, D'Innella, Pierluigi, Ballabio, Matteo, and Fornaro, Michele

Subjects
Adult, Male, Drug, medicine.medical_specialty, Pediatrics, Bipolar Disorder, Antimanic Agent, Substance-Related Disorders, medicine.drug_class, media_common.quotation_subject, Mild hyperammonemia, 03 medical and health sciences, 0302 clinical medicine, Antimanic Agents, Carnitine, neurotoxicity, medicine, Humans, Hyperammonemia, Clinical Case Report, 030212 general & internal medicine, Adverse effect, media_common, Valproic Acid, business.industry, organic chemicals, Mood stabilizer, General Medicine, Substance-Related Disorder, medicine.disease, ácido valproico, nervous system diseases, Surgery, Treatment Outcome, hepatic dysfunction, lipids (amino acids, peptides, and proteins), business, 030217 neurology & neurosurgery, Research Article, Human, medicine.drug
Abstract

Rationale: Valproic Acid is a commonly used psychiatric drug primarily used as a mood stabilizer. Mild hyperammonemia is a Valproic Acid common adverse effect. This report presents an example of treated hyperammonemia on Valproic acid therapy managed with L-carnitine administration in BD patients characterized by sudden vulnerability. Patient concerns: We report the case of a 29-year-old man suffering from bipolar disorder (BD) and substance use disorder who exhibited sudden altered mental status upon admittance to the inpatient unit. The patient was started on Valproic acid with no improvement. Diagnoses: The patient had remarkably high ammonia levels (594 μg/dL) without hepatic insufficiency, likely due to his valproate treatment. Interventions: The patient was administered lactulose, intravenous hydration, and i.v. levocarnitine supplementation 4.5 g/day. Outcomes: The administration leads to reduction of ammonia levels to 99 μg/dL within 12 hours upon initiation of carnitine therapy and progressive restore of his mental status within 24 hours. Lessons: Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine. An interesting aspect of this case was how rapidly the patient responded to the carnitine therapy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results